NovaBridge Biosciences (NBP) stock
Close on Nov 12, 2026Market cap $95.77MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- CN¥639.34M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 266M
Trading
- Previous close
- $0.86
- Open
- $0.90
- Day's range
- $0.82 – $0.90
- Volume
- 710,645
- Average volume (20 days)
- 528,165
- Beta (5 years)
- 1.48
- RSI (14 days)
- 19.7
- Volatility (1 year)
- 65.6%
- Relative volume
- 1.66×
- WACC
- 12.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NBP | S&P 500 | Difference | NBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.1% | -2.7% | −34.4 pts | ||
| 3 months | -55.6% | -1.7% | −53.9 pts | ||
| Year to date | -79.1% | +11.9% | −91.0 pts | ||
| 1 year | -80.3% | +12.0% | −92.3 pts | ||
| 3 years | -47.1% | +78.2% | −125.3 pts | -19.1% | +21.2% |
| 5 years | -98.6% | +73.2% | −171.9 pts | -57.5% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025, CNY
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases NovaBridge Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About NovaBridge Biosciences
Pharmaceutical Preparations
NovaBridge Biosciences is a clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel or differentiated biologic therapeutics. The company primarily directs its research efforts toward treatments in the fields of oncology and ophthalmology. It advances a proprietary pipeline of investigational drug candidates alongside partnered development programs with international pharmaceutical organizations. Its customer and collaborator base comprises global biopharmaceutical licensees, commercial healthcare providers, and targeted patient populations requiring advanced biologic interventions.
Company profile, executives and historyNovaBridge Biosciences stock: common questions
What is NovaBridge Biosciences's stock price?
NBP closed at $0.83 on Nov 12, 2026, down 3.60% on the day.
What is NovaBridge Biosciences's market cap?
NovaBridge Biosciences was worth $95.77M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does NovaBridge Biosciences pay a dividend?
No. NovaBridge Biosciences has not paid a cash dividend over the last twelve months.
How has NBP stock performed over the past year?
Including dividends, NBP returned -80.3% over the past year, against +12.0% for the S&P 500.
Who are NovaBridge Biosciences's competitors?
Companies most similar to NovaBridge Biosciences by business, industry and size include AAPG, APLM, HCM, ANL, LIANY.
See a number that looks wrong?